The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ioannidis, V.
Right arrow Articles by Held, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ioannidis, V.
Right arrow Articles by Held, W.
The Journal of Immunology, 2003, 171: 769-775.
Copyright © 2003 by The American Association of Immunologists

Initiation and Limitation of Ly-49A NK Cell Receptor Acquisition by T Cell Factor-11

Vassilios Ioannidis*, Béatrice Kunz*, Dawn M. Tanamachi{dagger}, Léonardo Scarpellino* and Werner Held2,*

* Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland; and {dagger} Department of Molecular and Cell Biology, University of California, Berkeley, CA 94729


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The establishment of clonally variable expression of MHC class I-specific receptors by NK cells is not well understood. The Ly-49A receptor is used by {approx}20% of NK cells, whereby most cells express either the maternal or paternal allele and few express simultaneously both alleles. We have previously shown that NK cells expressing Ly-49A were reduced or almost absent in mice harboring a single or no functional allele of the transcription factor T cell factor-1 (TCF-1), respectively. In this study, we show that enforced expression of TCF-1 in transgenic mice yields an expanded Ly-49A subset. Even though the frequencies of Ly-49A+ NK cells varied as a function of the TCF-1 dosage, the relative abundance of mono- and biallelic Ly-49A cells was maintained. Mono- and biallelic Ly-49A NK cells were also observed in mice expressing exclusively a transgenic TCF-1, i.e., expressing a fixed amount of TCF-1 in all NK cells. These findings suggest that Ly-49A acquisition is a stochastic event due to limiting TCF-1 availability, rather than the consequence of clonally variable expression of the endogenous TCF-1 locus. Efficient Ly-49A acquisition depended on the expression of a TCF-1 isoform, which included a domain known to associate with the TCF-1 coactivator {beta}-catenin. Indeed, the proximal Ly-49A promoter was {beta}-catenin responsive in reporter gene assays. We thus propose that Ly-49A receptor expression is induced from a single allele in occasional NK cells due to a limitation in the amount of a transcription factor complex requiring TCF-1.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Inhibitory receptors specific for MHC class I molecules ensure NK cell self-tolerance toward normal host tissues. The relief from MHC receptor-mediated inhibition, which occurs when target cells lose MHC class I expression, allows NK cells to kill such aberrant host cells. NK cell reactions to host cells lacking single MHC class I molecules can occur because some inhibitory MHC receptors recognize only certain MHC class I molecules and individual NK cells express various combinations, yet limited numbers of inhibitory receptors (for review, see Ref.1). Ligand selectivity combined with clonal distribution of inhibitory NK cell receptors also explains the reactivity of NK cells to allogeneic target cells (2). This property of NK cells is of clinical relevance, because it can be exploited in graft vs leukemia reactions (3).

Clonally variable expression of inhibitory NK cell receptors thus plays an important role for NK cell biology. However, it is not well understood how this diversity is established. Although the expression of CD94/NKG2A heterodimers is regulated by cytokines such as IL-15 (4), the regulation of human killer Ig-like receptors (KIR)3 or murine Ly-49 MHC class I receptors has remained obscure. However, bone marrow stroma is required for KIR or Ly-49 acquisition in vitro (5, 6). Furthermore, Ly-49 receptor expression shows some peculiar features. Ly-49 genes are normally expressed from a single and occasionally from both alleles (7, 8, 9), which is established independently of gene-recombination events (10). The patterns of KIR gene expression are maintained via DNA methylation (11, 12). The acquisition of distinct murine MHC receptors seems to occur at sequential stages of NK cell development, yet their coexpression is not mutually exclusive nor strongly interdependent (13, 14, 15). Finally, Ly-49 receptor expression is not directed by MHC class I molecules; however, the repertoire of these receptors on NK cells is modulated by MHC class I molecules (15, 16, 17, 18).

The prototype inhibitory MHC class I receptor in mice, the Ly-49A receptor is acquired by ~20% of NK cells (19). In contrast to other members of the Ly-49 receptor family, the acquisition of Ly-49A during NK cell development is stringently dependent on the trans-acting factor T cell factor-1 (TCF-1) (20, 21), whereas the close TCF-1 relative lymphoid enhancer factor-1 (LEF-1) is not required (22). Heterozygous TCF-1 mutant mice had 50% fewer Ly-49A NK cells than normal. This raised the possibility that TCF-1 was expressed by a subset of NK cells and that these NK cells acquired Ly-49A. Alternatively, TCF-1 may be expressed by all NK cells, but be rate limiting for Ly-49A acquisition, such that only some NK cells acquired Ly-49A.

TCF-1 and other members of the TCF/LEF family (i.e., TCF-1, TCF-3, TCF-4, and LEF-1) bind DNA in a sequence-specific manner, yet possess no intrinsic ability to modulate transcription (23). Nevertheless, TCF/LEF factors contribute to transcriptional responses in reporter gene assays in various ways. For instance, LEF-1 was shown to play an architectural role, which depended on DNA bending. This facilitated the formation of a transcriptionally competent higher order nucleoprotein complex at the minimal TCR {alpha} enhancer (24, 25, 26). All TCF/LEF factors can serve as docking molecules for cofactors, which upon interaction with DNA-binding TCF/LEF alter the transcriptional activity of a nearby promoter. The association with Groucho/transducin-like enhancer of split (TLE) proteins leads to promoter repression (27), while {beta}-catenin is an interaction partner, which activates transcription (28, 29). The availability of {beta}-catenin as an interaction partner for TCF/LEF is regulated by extrinsic factors such as some members of the wnt family of signaling molecules. TCF/LEF thus act as nuclear effectors of the canonical wnt signaling pathway, which plays important roles in embryogenesis, the establishment and/or maintenance of self-renewing tissues, and tumorigenesis (28, 29, 30, 31).

The interaction of TCF/LEF with the coactivator {beta}-catenin or Groucho/TLE corepressors is mediated via distinct, nonoverlapping domains (27). This property has allowed us to begin to dissect the dependence of Ly-49A acquisition on a particular function of TCF-1. We find that a {beta}-catenin-responsive TCF-1 isoform is required for Ly-49A acquisition by NK cells and that this was a rare event due to a limiting TCF-1 dosage.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Mice

C57BL/6 (B6) and BALB.B mice were purchased from Harlan Olac (Horst, The Netherlands). Tcf-1 (exon VII)-deficient mice have been described before (32). Tcf-1 transgenic (Tg) mice were generated by inserting human p45 TCF-1 (25) or the murine p33 TCF-1 (M2a) (33) cDNA clones into the H-2Kb promoter-Igµ enhancer cassette (34), as described (35). Tg mice were generated by standard methods using fertilized (B6 x DBA/2)F2 oocytes. Tg lines were established by backcrossing to B6 and TCF-1-defcient mice. The B6 origin of the NK gene complex (NKC) and the MHC were ascertained using flow cytometry with B6 allele-specific mAbs A1 (Ly-49A) and PK136 (NK1.1) and mAbs specific for H-2Db (KH-95) and H-2Dd (34.2.12) (BD PharMingen, San Diego, CA), respectively. NKC heterozygous mice were obtained by crossing BALB.B mice with NKC B6 mice of the various TCF-1 genotypes. TCF-1-deficient (±TCF-1B transgene) NKCF1 mice were obtained by further backcrossing to TCF-1-deficient (±TCF-1B transgene) NKC B6 mice and selecting for NKC F1 mice based on an intermediate intensity of staining with the B6 allele-specific mAb PK136 (NK1.1).

DNA analysis

Tg mice were identified by Southern blotting using 10 µg of tail DNA digested with EcoRV. Blots were hybridized with a randomly primed ~800-bp XhoI fragment derived from Tcf-1 cDNA that covers most of Tcf-1 exon X. Hybridizing bands of 13 and 8 kb are diagnostic for wild-type and transgenic TCF-1, respectively. Alternatively, Tg offspring was identified by PCR using tail DNA as a template and the following primers: murine Tcf-1, sense 5'-GCC AGC CTC CAC ATG GCG TC; human Tcf-1, sense 5'-GCG GCA TGT ACA AAG AGA CC; hu/mu Tcf-1, anti, 5'-CGG GTG AGG GAT GGC TGC TG. TCF-1 transgenic, TCF-1-deficient mice were identified using PCR with the following primers: TCF-1 exon, VI TGC TGA GTG CAC ACT CAA GG; TCF-1 exon, VII GTA GTT ATC CCG CGC GGA CC; Neo, ATG GCG ATG CCT GCT TGC CGA ATA.

Products of 600, 250, and 150 bp are specific for TCF-1 knockout, wild type, and Tg, respectively. For PCR, we used AmpliTaq DNA polymerase (Roche Diagnostics, Somerville, NJ) and 300 nM final concentration of each primer. Cycling conditions were 3 min at 92°C, 40 cycles at 92°C for 1 min, 58°C for 1 min, and 72°C for 1 min. PCR products were separated by agarose gel electrophoresis and visualized under UV.

Flow cytometry and cell sorting

One million nylon wool-nonadherent spleen or bone marrow cells were reacted with 24G2 (anti CD16/32) hybridoma supernatant to reduce background. The cells were stained for three- or four-color flow cytometry with mixtures of FITC-labeled anti-Ly-49A (JR9-318) or anti-Ly-49ABALB (TNTA (9)), anti-NK1.1 PE (PK136) or anti-DX5 PE, anti-CD3 CyChrome (2C11), and biotinylated anti-Ly-49AB6 (A1). The latter was revealed using allophycocyanin-conjugated streptavidin (Molecular Probes, Eugene, OR). Dead cells were excluded by appropriate gating of forward scatter and side scatter. A total of 5 x 104 to 105 viable cells was run on a FACScan flow cytometer and analyzed using CellQuest software (BD Biosciences, San Jose, CA).

Before intracellular TCF-1 staining, nylon wool-nonadherent spleen cells were surface labeled with anti-CD3 Cy and DX5 FITC, washed, and fixed for 10 min in PBS/2% paraformaldehyde at room temperature. After one wash in PBS, the cells were incubated for 1 h with anti-human TCF-1 mAb (7H3) (36) diluted in PBS/3% FCS/0.5% saponin (Sigma-Aldrich, Buchs, Switzerland). Cells were then washed once in PBS/3% FCS/0.5% saponin and incubated for 1 h with a Cy3-conjugated goat anti-mouse IgG1 Ab (Jackson ImmunoResearch, West Grove, PA). After one wash in PBS/3% FCS/0.5% saponin, cells were resuspended in PBS/3% FCS and analyzed, as above.

Western blot

IL-2-expanded, plastic-adherent cells (1 x 106, >90% NK1+ CD3- cells) were washed once in PBS and lysed in sample buffer (62.4 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 5% 2-ME, and 0.02% bromphenol blue). Samples were boiled for 5 min before SDS-PAGE and blotted onto Hybond ECL nitrocellulose membranes (Amersham, Little Chalfont, U.K.). Blots were blocked with 5% dry milk in PBS containing 0.005% Tween (PBS-T) and incubated overnight at 4°C with the primary Ab. The following Abs were used: rabbit anti-TCF-1 (37) (kindly provided by Y. Katsura, Kyoto, Japan) and mouse anti-{alpha}-tubulin (B-5-1-2; Sigma-Aldrich). After washing, HRP-conjugated secondary Abs to mouse or rabbit IgG (Sigma-Aldrich) were added for 1 h at room temperature. Western blots were revealed using an ECL detection kit (Pierce, Rockford, IL). Blots were stripped for 30 min at 50°C in stripping buffer (2% w/v SDS, 62.5 mM Tris-HCl, pH 6.8, 100 mM 2-ME) before reprobing.

Transfections and reporter gene assays

The 5' region (-1066 (EcoRI) to +44 (EcoRV)) of the Ly-49A gene (38) and the corresponding fragment, in which the two TCF/LEF sites were mutated, were inserted into the luciferase (luc) reporter plasmid pGL3 (Promega, Madison, WI). This construct was sequenced to ensure that only the intended mutations were introduced. The expression constructs for {beta}-catenin and {beta}-catenin-TCF/LEF reporter plasmids (pTOPFLASH and control pFOPFLASH) were described before (39). Human 293 cells were transfected using Ca phosphate, and the cells were collected and assayed for luciferase activity after 48 h. CMV-enhanced green fluorescence protein or CMV-renilla luciferase expression constructs were cotransfected to normalize for transfection efficiency. Transfections were done using 1 µg of green fluorescence protein or 50 ng of renilla control plasmid with 4 µg of luciferase reporter and 5 µg of expression {beta}-catenin expression plasmid. Where needed, appropriate empty expression vectors were added to keep the amount of DNA constant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Ly-49A acquisition in TCF-1 transgenic mice

We have previously shown that the acquisition of the Ly-49A NK cell receptor was dependent on the trans-acting factor TCF-1. TCF-1 seemed to limit Ly-49A acquisition, based on a 2-fold smaller Ly-49A NK cell subset in mice with a single as compared with two functional TCF-1 alleles (20). This was not due to differential expression of TCF-1 in Ly-49A+ vs Ly-49A- cells, because comparable levels of TCF-1 protein were detected in the two NK cell subsets (Fig. 1a).



View larger version (34K):
[in this window]
[in a new window]
  		FIGURE 1. TCF-1 expression and TCF-1 transgenic mice. a, IL-2-expanded NK cells (CD3- NK1.1+) were sorted into Ly-49A+ and Ly-49A- subsets. Nuclear extracts prepared from 106 sorted cells were subjected to immunoblot analysis with a polyclonal antiserum to TCF-1. Arrows indicate TCF-1 p45 and p33 isoforrms. Equal protein loading was ensured by Ponceau red staining. b, The TCF-1 p45 isoform includes a DNA binding domain, a domain that mediates the interactions with corepressors of the Groucho family, and a NH2-terminal {beta}-catenin binding domain. The latter domain is not present in the naturally occurring p33 isoform.

 
To functionally address the basis for the limited Ly-49A acquisition, we analyzed mice expressing a p45 TCF-1 isoform (Fig. 1b) under the control of the H-2Kb promoter/Igµ enhancer expression cassette (35). In Tg mice, CD3- DX5+ splenic NK cells expressed the human TCF-1 protein at appreciable and uniform levels, as judged by intracellular flow cytometry specific for the transgenic TCF-1. Based on the mean fluorescence intensity of staining, NK cells from Tg line 2 expressed somewhat higher levels of the Tg TCF-1 as compared with line 11 (Fig. 2a). Moreover, p45 Tg levels in IL-2-expanded NK cells were comparable, yet below those of endogenous TCF-1 based on Western blot analyses (Fig. 2b).



View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 2. Expression of TCF-1 transgenes. a, Anti-CD3 and DX5 surface-labeled nylon wool-enriched spleen cells were stained intracellularly (ic.) with an anti-human TCF-1 mAb, followed by Cy3-conjugated goat anti-mouse IgG1 Ab, and analyzed using flow cytometry. Nontransgenic littermate mice served as a genetic control. Histograms show intracellular human TCF-1 among gated CD3- DX5+ NK cells in p45 Tg line 2 or 11 (thick lines) as compared with non-Tg littermate mice (gray histogram). Numbers in brackets indicate the mean fluorescence intensity (MFI) of staining. b, IL-2-expanded NK cells from B6+/+, TCF-1-deficient-/-, p45, and p33 Tg TCF-1-deficient mice were sorted. Nuclear extracts prepared from 106 cells were subjected to immunoblot analysis using a polyclonal rabbit anti-TCF-1 antiserum. Ponceau red staining of the membrane was used to ensure equal protein loading.

 
The impact of Tg expression on Ly-49A NK cell receptor usage was investigated using B6 backcross two to four mice. All mice were lacking the strong Ly-49A ligand H-2Dd to avoid modulation of Ly-49A usage based on Ly-49-MHC class I interactions. Moreover, they all harbored two B6-derived copies of the NK gene complex, which contains the polymorphic Ly-49 gene cluster. As shown in Fig. 3a, the Ly-49A NK cell subset in spleens of Tg lines 2 and 11 was significantly expanded (36.4 ± 5.5% and 30.6 ± 1.6 of NK cells, respectively) as compared with non-Tg littermate (18.3 ± 2.9) or B6 mice (19.1 ± 2.8). Corresponding results were obtained in the bone marrow, where NK cells arise (not shown). These findings, together with our earlier analysis of the Ly-49A NK cell subsets in TCF-1-deficient (1.3 ± 0.4) and TCF-1-hemizygous mice (9.5 ± 1.5) (20), suggested that in both, loss of function and gain of function approaches, the extent of Ly-49A acquisition was related to the TCF-1 gene dosage (Fig. 3b). Importantly, the sizes of the splenic or bone marrow NK cell compartments in most types of mice were not significantly different (Fig. 3c and data not shown) even under conditions of competitive reconstitution in radiation bone marrow chimeras (data not shown). Reduced numbers of NK cells were observed, however, in the bone marrow and less so in the spleen of mice lacking TCF-1 (Fig. 3c) (20). Therefore, the expanded, yet still limited usage of Ly-49A in TCF-1 transgenic mice was observed even though TCF-1 was expressed in most, if not all, NK cells. These findings suggest that the TCF-1 dosage may be rate limiting for all-or-none Ly-49A acquisition events.



View larger version (55K):
[in this window]
[in a new window]
  		FIGURE 3. Ly-49A acquisition is influenced by the TCF-1 gene dosage. a, Dot plots show nylon wool-nonadherent spleen cells stained with mAbs to CD3 and NK1.1 in the indicated types of mice. Numbers indicate the mean percentage (±SD) of NK1.1+ CD3- NK cells of three or more mice. Histograms show Ly-49A usage among gated NK1.1+ CD3- NK cells. Numbers indicate the mean percentage (±SD) of Ly-49A+ NK cells of the above mice. b, Bar graphs show the percentage of Ly-49A+ NK cells among splenic NK cells of the indicated strains of mice. Data indicate mean percentage (±SD) of seven or more independent determinations. c, Bar graphs show the absolute numbers of NK cells in spleens of the indicated types of mice. Data are derived from nylon wool-nonadherent cells and are shown as mean absolute number (±SD) of seven or more independent determinations.

 
TCF-1 regulates the acquisition of individual Ly-49A alleles

Consistent with a rate-limiting role of a trans-acting factor, Ly-49A as well as additional Ly-49 genes, NKG2A, KIR, and several cytokine genes belong to a class of nonrearranging/nonimprinted and non-X-linked loci with predominant monoallelic expression (7, 8, 12, 40, 41, 42, 43). To investigate whether TCF-1 regulated monoallelic Ly-49A expression, we took advantage of mAbs A1 and TNTA, which specifically react with Ly-49A alleles of B6 and BALB origin, respectively (Fig. 4a) (7, 9).



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 4. The TCF-1 gene dosage influences mono- and biallelic Ly-49A expression. Dot plots depict an expression analysis of Ly-49A alleles among gated DX5+ CD3- NK cells. a, Control staining using B6 (H-2b) and BALB.B (H-2b) NK cells was used to ensure the specificity of the mAbs. The Ly-49AB6 allele was detected using mAb A1, while mAb TNTA is specific for Ly-49ABALB. An artificial mixture of B6 and BALB.B cells ensured that no artifactual A1+TNTA+ cells were detected. Numbers indicate the percentage of cells in the respective quadrants of a representative experiment. b, NK cells from mice with the indicated TCF-1 genotypes and with a heterozygous B6/BALB.B NK gene complex (NKC) were analyzed for Ly-49AB6 (using mAb A1) and Ly-49ABALB (mAb TNTA) usage. Numbers indicate the percentage of cells in the respective quadrants of a representative experiment. c, Ly-49AB6 (mAb A1) and Ly-49ABALB (mAb TNTA) usage among NKCB6/BALB heterozygous mice of the indicated TCF-1 genotypes. Data are depicted as mean values (±SD) and are derived from three or more mice of each type. d, Experimental values (open bars) indicate the percentage of NK cells, which simultaneously express the Ly-49AB6 and Ly-49ABALB alleles (A1+ TNTA+ double-positive NK cells). Filled bars indicate the predicted value for independent acquisition of the two alleles. This value was calculated for each mouse by multiplying the percentage of A1+ NK cells with that of TNTA+ NK cells divided by 100.

 
Compared with non-Tg mice, the usage of the B6 allele (A1+ NK cells) was increased 3- and 2-fold in TCF-1 Tg (B6 x BALB.B)F1 mice of lines 2 and 11, respectively. The usage of the BALB allele (TNTA+ cells) was increased 2- and 1.5-fold in lines 2 and 11, respectively (Fig. 4, b and c). An elevated TCF-1 gene dosage introduced a slight allelic bias toward B6. The analysis of F1 mice with a reduced TCF-1 dosage (TCF-1+/- and TCF-1-/- mice) produced essentially a mirror image of the above results (Fig. 4, b and c). Compared with TCF-1+/+ mice, the usage of the B6 allele (A1+ NK cells) decreased 2- and 15-fold in TCF-1+/- and TCF-1-/- mice, respectively, whereas that of the BALB allele (TNTA+ NK cells) decreased 1.5- and 4-fold (Fig. 4). Decreasing TCF-1 gene dosages reduced the acquisition of either Ly-49A allele, whereby the BALB allele was less affected. The TCF-1 gene dosage thus regulates the acquisition of individual Ly-49A alleles in F1 NK cells.

A fraction of Ly-49A+ NK cells in normal mice expresses simultaneously both alleles. To investigate whether the development of such NK cells was also regulated by TCF-1, we first used an artificial mixture of B6 and BALB.B NK cells to ensure that the flow cytometric analysis did not detect artifactual A1+TNTA+ double-positive NK cells (Fig. 4a). Among TCF-1+/+ (B6 x BALB.B)F1 mice, 2.0 ± 0.5% of total NK cells simultaneously expressed both Ly-49A alleles (Fig. 4d). The frequency of biallelic Ly-49A NK cells increased to 8.9 ± 0.8% in Tg TCF-1+/+ mice and decreased to 0.2 ± 0.1% in TCF-1-/- mice. The TCF-1 gene dosage thus also regulates the development of cells that express simultaneously both Ly-49A alleles. Abundant biallelic expression of Ly-49A cells may be the result of an increased expression of the endogenous TCF-1 locus in some immature NK cells. To address this possibility, we analyzed TCF-1 Tg (line 2) TCF-1-/- (B6 x BALB.B)F1 mice. NK cells in these mice displayed a pattern of Ly-49A usage, which was essentially identical with that of TCF-1+/+ F1 mice (Fig. 4, b–d). Therefore, allele-specific Ly-49A expression patterns do not arise through clonally variable expression of the endogenous TCF-1 locus. Rather, the frequency of biallelic Ly-49A NK cells increased in relation to the increases in cells expressing either Ly-49A allele. Biallelic Ly-49A expression thus seems to be the product of coincidental expression of the two Ly-49A alleles in a single cell. Indeed, the percentage of biallelic Ly-49A cells observed was always within a factor of two of the percentage expected if the two alleles are expressed independently (Fig. 4d). These findings are in very good agreement with the view that Ly-49A acquisition is regulated via a rate-limiting amount of TCF-1.

Ly-49A acquisition is dependent on a {beta}-catenin-responsive TCF-1 isoform

The mechanism by which TCF-1 mediates Ly-49A acquisition may contribute to its role as a rate-limiting factor. The function of TCF/LEF is dependent on interactions with cofactors, which are mediated by distinct domains in TCF/LEF proteins. This property has allowed us to begin to dissect the dependence of Ly-49A acquisition on a particular function of TCF-1. In addition to p45, we have analyzed transgenic mice, which express a p33 TCF-1 Tg (35). This naturally occurring TCF-1 isoform includes the DNA as well as the Groucho/TLE binding domains, yet lacks the {beta}-catenin interaction domain present in p45 (Fig. 1b). Both types of transgenic mice were backcrossed to mice lacking endogenous TCF-1 (35).

Western blot analyses of whole cell lysates from IL-2-cultured NK cells revealed comparable amounts of TCF-1 in p45 and p33 transgenic mice. Moreover, the levels of the Tg TCF-1 were comparable, yet below those of endogenous TCF-1 (Fig. 2b). These findings corroborate our previous analysis of TCF-1 Tg expression in thymocytes (35).

The expression of the p45 transgene (in the absence of endogenous TCF-1) restored Ly-49A usage by NK cells to levels observed in TCF-1+/+ mice (Fig. 5A). Consistent with the somewhat higher TCF-1 Tg expression (Fig. 2a), the Ly-49A NK cell subset in line 2 was larger (22.8 ± 3.8% of NK cells) as compared with line 11 (13.9 ± 3.2%). In contrast, the p33 Tg, which was expressed at levels similar to p45, resulted only in a minor effect on Ly-49A usage (Fig. 5, a and b). The p33 Tg did not act in a dominant-negative fashion based on the observation that the Ly-49A NK cell subset was slightly larger (rather than reduced) in TCF-1+/+ p33Tg (24.0 ± 2.2) as compared with TCF-1+/+ (18.0 ± 2.6) mice. The findings thus suggest that the repressor and context-dependent functions of TCF-1, which can be mediated by p33, are not critical for Ly-49A acquisition. However, the N-terminal domain in TCF-1, which includes a {beta}-catenin binding site, is essential for the acquisition of the Ly-49A NK cell receptor in vivo. Clonal Ly-49A expression thus seems to be established via {beta}-catenin/TCF-1-dependent activation of Ly-49A and not by the inactivation of initially expressed alleles.



View larger version (54K):
[in this window]
[in a new window]
  		FIGURE 5. A {beta}-catenin-responsive TCF-1 isoform is required for Ly-49A acquisition. a, Dot plots show nylon wool-nonadherent spleen cells stained with mAbs to CD3 and NK1.1 in the indicated types of mice. Numbers indicate the mean percentage (±SD) of NK1.1+ CD3- NK cells of five or more mice. Histograms show Ly-49A usage among gated NK1.1+ CD3- NK cells. Numbers indicate the mean percentage (±SD) of Ly-49A+ NK cells of the above mice. b, Bar graphs show the percentage of Ly-49A+ NK cells among splenic NK cells of the indicated TCF-1 transgenic lines. Data indicate mean percentage (±SD) of 3–11 independent determinations.

 
The Ly-49a promoter is {beta}-catenin responsive

To test whether the Ly-49a promoter was {beta}-catenin responsive, we chose 293 cells, which express all the TCF/LEF family factors as interaction partners for {beta}-catenin (44). Indeed, the transfection with {beta}-catenin trans-activated the Ly-49a promoter 2- to 3-fold in reporter gene assays (Fig. 6). That was of comparable magnitude to the trans activation obtained for other TCF/LEF target genes such as myc or cyclin D1 (45, 46). Similar to some other TCF/LEF target genes, no further promoter induction was obtained by cotransfecting p300, which represents a {beta}-catenin coactivator (47) (data not shown). The Ly-49a promoter contains two consensus TCF/LEF binding sites (CTTTGA/TA/T) close to the transcriptional start site (Fig. 6a) (20). Point mutations in the two binding sites increased the basal promoter activity in 293 cells, suggesting that in the absence of {beta}-catenin the wild-type Ly-49a promoter was repressed by TCF/LEF. That is in agreement with findings for other TCF/LEF target genes (48). Importantly, the mutant Ly-49a promoter was no longer {beta}-catenin responsive, suggesting that the induction by {beta}-catenin is mediated by TCF/LEFs (Fig. 6b). These findings suggest that the Ly-49a promoter is a direct target of TCF/LEF-{beta}-catenin complexes.



View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 6. The Ly-49a promoter is {beta}-catenin responsive. a, The Ly-49a promoter contains two consensus TCF/LEF binding sites (denoted I and II) close to the transcriptional start site (arrow). b, Human 293 cells were transiently transfected with Ly-49a promoter-luciferase (luc) reporter constructs containing either wild-type or mutant TCF/LEF sites. Both reporters were tested in the presence of a {beta}-catenin or an empty pCDNA expression plasmid. Data were normalized to show induction of luciferase activity by {beta}-catenin relative to the absence of {beta}-catenin (left panel) and relative luciferase activity of the different constructs (right panel). Data represent mean values (±SD) of six independent experiments.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The Ly-49A receptor is acquired by some, but not all NK cells during development. The data presented in this work are compatible with the view that the stable induction of Ly-49A gene expression is regulated by the formation of a nucleoprotein complex at the Ly-49A promoter, which requires TCF-1. Indeed, Ly-49A acquisition is dependent on a {beta}-catenin-receptive TCF-1 isoform, and the Ly-49a promoter is {beta}-catenin responsive in reporter gene assays. These findings suggest the requirement of a complex, which includes TCF-1 as well as its coactivator {beta}-catenin. TCF-1 seems to represent a rate-limiting factor, such that the assembly of a functional complex at the Ly-49A promoter occurs only in occasional NK cells. The TCF-1 dosage may thus set a probability of Ly-49A acquisition at the population level, and modulation of the TCF-1 gene dosage alters the likelihood for all-or-non-Ly-49A acquisition events.

The question as to whether cellular signaling results in binary (on/off) or graded transcriptional responses in individual cells has recently received renewed attention. Indeed, the competition between activators and repressors of transcription produced a binary response in distinct model systems. In both cases, the concentration of the exogenous stimulating agent influenced the proportion of cells expressing a reporter gene rather than the rate of transcription in each cell (49, 50). Similarly, for the developmentally regulated acquisition of Ly-49A, the TCF-1 dosage would influence the probability to stably switch on Ly-49A expression.

We have previously shown high (50-fold) reporter gene activation by the Ly-49a promoter in EL-4 cells (20). This activity was further increased by transfecting p33 (1.3-fold) (20) or p45 (1.9-fold over the constitutive activity) (not shown). These effects were observed in the absence of significant activation of the TCF optimal promoter reporter gene, which depends on the presence of TCF/{beta}-catenin complexes. These data suggested that {beta}-catenin was not required for Ly-49a promoter activity in a cell line with constitutive expression of the endogenous Ly-49a locus. The behavior of the Ly-49a promoter was thus similar to that of the minimal TCR{alpha} enhancer, which was induced by either p33 or p45 in a B cell line (25). Reporter gene activity in these situations may thus reflect an architectural role of TCF-1, which may play a role in maintaining constitutive gene expression.

In contrast to EL-4, Ly-49A promoter activity in 293 cells is low (3-fold over a promoterless construct) (20). This activity was augmented 2.5-fold by the addition of {beta}-catenin (Fig. 6). In this situation, endogenous TCF/LEFs are used to mediate reporter gene activation. Indeed, 293 cells express all four TCF/LEF family members (44). This is indicated by the fact that reporter gene activation was only observed with the wild-type Ly-49A promoter, which contains two TCF binding sites, but not with the control promoter, which contains mutant sites. Although we show that {beta}-catenin/TCF functionally interact with the Ly-49a promoter, the physiological consequence of this binding in chromatin may be the modification of local chromatin structure via associated p300/CBP or Brg (47, 51, 52). That would explain its apparent role as a developmental switch.

A role of TCF-1 as an on switch incorporates a particular feature of Ly-49A gene expression: most Ly-49A+ NK cells express a single receptor allele. Complex formation in an individual NK cell seems to suffice only to initiate Ly-49A expression only from a single Ly-49A allele. The observation that individual NK cells can express either the maternal or the paternal allele is consistent with this possibility, as the formation of the factor complex may occur randomly on either chromosome. In addition, some Ly-49A NK cells express simultaneously both alleles. Such cells are also observed when NK cells express a fixed amount of TCF-1 (in TCF-1 Tg TCF-1-/- mice), suggesting that they develop independently of clonal variations in TCF-1 levels. Rather, the fraction of NK cells expressing both Ly-49A alleles increased in parallel to the increased usage of the individual alleles, suggesting that biallelic Ly-49A gene expression is a function of the chance that the expression of the two alleles coincides. In fact, the percentage of NK cells expressing simultaneously both alleles (A1+TNTA+ NK cells) indicates whether the two alleles are expressed independently. Purely stochastic expression of the two alleles is predicted when the frequency of double expressors matches the product of the frequency to express either Ly-49A allele (also termed product rule (53)). In our analyses, the experimental value was always within a factor of two of the predicted one (Fig. 4d). The slight overrepresentation of biallelic Ly-49A cells occurred thus independent of the TCF-1 gene dosage and was not related to the expression pattern of the endogenous TCF-1 locus. These findings suggest that factors other than TCF-1 introduce this bias.

The comparison of (B6 x BALB.B)F1 mice, expressing variable amounts of TCF-1, revealed another unexpected feature. Changes in the TCF-1 dosage resulted in the biased usage of the B6 vs the BALB Ly-49A alleles (Fig. 4c). One possibility is that TCF-1 binds preferentially to the B6 allele of Ly-49A. Indeed, there exist two nucleotide differences between the proximal Ly-49A promoter of BALB and B6 origin (B. Kunz and W. Held, unpublished observation). Although these polymorphisms do not locate directly to the two consensus TCF binding sites, they are in their vicinity and may thus influence the binding of additional trans-acting factors involved in Ly-49A acquisition. Alternatively, an allelic bias could in principle result from a differential MHC class I-dependent effect on NK cells, which have acquired the B6 as compared with the BALB allele of Ly-49A. However, we have used H-2b mice for our analyses, in which the two Ly-49A alleles do not encounter a class I ligand that is sufficient to inhibit NK cells (54). Nevertheless, it cannot be excluded that the two alleles display some differential affinity for class I (55), which may be sufficient to influence the Ly-49 receptor repertoire.

Our findings indicate that Ly-49A acquisition is limited via the TCF-1 dosage and occurs in a {beta}-catenin-dependent fashion. It is thus possible that, similar to TCF-1, the levels of {beta}-catenin in NK cells influence Ly-49A acquisition. The availability of intracellular free {beta}-catenin is dependent on extrinsic factors such as wnt family proteins (30). In this context, it is known that bone marrow stromal cells as well as hemopietic cells express wnts (56) (our unpublished observation). Wnt5a is expressed in primary bone marrow stroma cells, while wnt10b and wnt3a are expressed by hemopoietic cells (56). Indeed, stroma cells allow the acquisition of Ly-49A in in vitro NK cell differentiation assays (5, 13, 14). Thus, our analysis raises the possibility that wnts represent one of the elusive signals to initiate Ly-49 expression by developing NK cells.


   Acknowledgments
 
We are grateful to D. H. Raulet (University of California) for providing TNTA mAb, Y. Katsura (Osaka, Japan) for anti-TCF-1 antiserum, and H. Clevers (Utrecht, The Netherlands) for TCF-1-deficient mice and anti-TCF-1 mAb. We thank P. Zaech for expert cell sorting and H. R. MacDonald and J.-C. Cerottini for critical reading of the manuscript.


   Footnotes
 
1 This work has been supported in part by a Swiss Talents for Academic Research and Teaching fellowship and a grant from the Swiss National Science Foundation to W.H. Back

2 Address correspondence and reprint requests to Dr. Werner Held, Ludwig Institute for Cancer Research, Lausanne Branch, Ch. des Boveresses 155, 1066 Epalinges, Switzerland. E-mail address: wheld{at}isrec.unil.ch Back

3 Abbreviations used in this paper: KIR, killer Ig-like receptor; LEF, lymphoid enhancer factor; NKC, NK gene complex; TCF-1, T cell factor-1; Tg, transgene/transgenic; TLE, transducin-like enhancer of split. Back

Received for publication March 12, 2003. Accepted for publication May 19, 2003.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Raulet, D. H., R. E. Vance, C. W. McMahon. 2001. Regulation of the natural killer cell receptor repertoire. Annu. Rev. Immunol. 19:291.[Medline]
  2. Held, W., D. Cado, D. H. Raulet. 1996. Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection. J. Exp. Med. 184:2037.[Abstract/Free Full Text]
  3. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, et al 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097.[Abstract/Free Full Text]
  4. Mingari, M. C., M. Ponte, S. Bertone, F. Schivetta, C. Vitale, R. Bellomo, A. Moretta, L. Moretta. 1998. HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen or alloantigen-activated CD8+ T cells. Proc. Natl. Acad. Sci. USA 95:1172.[Abstract/Free Full Text]
  5. Williams, N. S., J. Klem, I. J. Puzanov, P. V. Sivakumar, M. Bennett, V. Kumar. 1999. Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent progenitor cells. J. Immunol. 163:2648.[Abstract/Free Full Text]
  6. Miller, J. S., V. McCullar. 2001. Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood 98:705.[Abstract/Free Full Text]
  7. Held, W., J. Roland, D. H. Raulet. 1995. Allelic exclusion of Ly49 family genes encoding class I-MHC-specific receptors on NK cells. Nature 376:355.[Medline]
  8. Held, W., B. Kunz. 1998. An allele-specific, stochastic gene expression process controls the expression of multiple Ly49 family genes and generates a diverse, MHC-specific NK cell receptor repertoire. Eur. J. Immunol. 28:2407.[Medline]
  9. Tanamachi, D. M., T. Hanke, H. Takizawa, A. M. Jamieson, D. H. Raulet. 2001. Expression of natural killer receptor alleles at different Ly49 loci occurs independently and is regulated by major histocompatibility complex class I molecules. J. Exp. Med. 193:307.[Abstract/Free Full Text]
  10. Held, W., B. Kunz, V. Ioannidis, B. Lowin-Kropf. 1999. Mono-allelic Ly49 NK cell receptor expression. Semin. Immunol. 11:349.[Medline]
  11. Santourlidis, S., H.-I. Trompeter, S. Weinhold, B. Eisermann, K. L. Meyer, P. Wernet, M. Uhrberg. 2002. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J. Immunol. 169:4253.[Abstract/Free Full Text]
  12. Chan, H.-W., Z. B. Kurago, C. A. Stewart, M. J. Wilson, M. P. Martin, B. E. Mace, M. Carrington, J. Trowsdale, C. T. Lutz. 2003. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J. Exp. Med. 197:245.[Abstract/Free Full Text]
  13. Roth, C., J. Carlyle, H. Takizawa, D. H. Raulet. 2000. Clonal acquisition of inhibitory Ly49 receptors on developing NK cells is successively restricted and regulated by stromal class I MHC. Immunity 13:143.[Medline]
  14. Williams, N. S., A. Kubota, M. Bennett, V. Kumar, F. Takei. 2000. Clonal analysis of NK cell development from bone marrow progenitors in vitro: orderly acquisition of receptor gene expression. Eur. J. Immunol. 30:2074.[Medline]
  15. Held, W., J. R. Dorfman, M.-F. Wu, D. H. Raulet. 1996. Major histocompatibility complex class I dependent skewing of the natural killer cell Ly49 receptor repertoire. Eur. J. Immunol. 26:2286.[Medline]
  16. Held, W., D. H. Raulet. 1997. Ly49A transgenic mice provide evidence for a major histocompatibility complex-dependent education process in natural killer cell development. J. Exp. Med. 185:2079.[Abstract/Free Full Text]
  17. Fahlén, L., U. Lendhal, C. L. Sentman. 2001. MHC class I-Ly49 interactions shape the Ly49 repertoire on murine NK cells. J. Immunol. 166:6585.[Abstract/Free Full Text]
  18. Hanke, T., H. Takizawa, D. H. Raulet. 2002. MHC-dependent shaping of the inhibitory Ly49 receptor repertoire on NK cells: evidence for a regulated sequential model. Eur. J. Immunol. 31:3370.
  19. Karlhofer, F. M., R. K. Ribaudo, W. M. Yokoyama. 1992. MHC class I alloantigen specificity of Ly-49+ IL-2 activated natural killer cells. Nature 358:66.[Medline]
  20. Held, W., B. Kunz, B. Lowin-Kropf, M. van de Wetering, H. Clevers. 1999. Clonal acquisition of the Ly49A NK cell receptor is dependent on the trans-acting factor TCF-1. Immunity 11:433.[Medline]
  21. Kunz, B., W. Held. 2001. Positive and negative roles of the trans-acting factor TCF-1 for the acquisition of distinct Ly49 MHC class I receptors by NK cells. J. Immunol. 166:6181.[Abstract/Free Full Text]
  22. Held, W., H. Clevers, R. Grosschedl. 2003. Redundant functions of TCF-1 and LEF-1 during T and NK cell development, but unique role of TCF-1 for Ly49 NK cell receptor acquisition. Eur. J. Immunol. 33:1393.[Medline]
  23. Van de Wetering, M., W. de Lau, H. Clevers. 2002. WNT signaling and lymphocyte development. Cell 109:13.
  24. Giese, K., C. Kingsley, J. R. Kirshner, R. Grosschedl. 1995. Assembly and function of a TCR{alpha} enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions. Genes Dev. 9:995.[Abstract/Free Full Text]
  25. Van de Wetering, M., J. Gastrop, V. Korinek, H. Clevers. 1996. Extensive alternative splicing and dual promoter usage generate TCF-1 protein isoforms with differential transcription control properties. Mol. Cell. Biol. 16:745.[Abstract]
  26. Hsu, S.-H., J. Galceran, R. Grosschedl. 1998. Modulation of transcriptional regulation by LEF-1 in response to Wnt-1 signaling and association with {beta}-catenin. Mol. Cell. Biol. 18:4807.[Abstract/Free Full Text]
  27. Roose, J., M. Molenaar, J. Peterson, J. Hurenkamp, H. Brantjes, P. Moerer, M. van de Wetering, O. Destrée, H. Clevers. 1998. The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature 395:608.[Medline]
  28. Molenaar, M., M. van de Wetering, M. Oosterwegel, J. Peterson-Maduro, V. Korinek, J. Roose, O. Destree, H. Clevers. 1996. XTcf-3 transcription factor mediates {beta}-catenin-induced axis formation in Xenopus embryos. Cell 86:391.[Medline]
  29. Behrens, J., J. P. von Kries, M. Kühl, L. Bruhm, D. Wedlich, R. Grosschedl, W. Birchmeier. 1996. Functional interaction of {beta}-catenin with the transcription factor LEF-1. Nature 382:638.[Medline]
  30. Cadigan, K. M., R. Nusse. 1997. Wnt signaling: a common theme in animal development. Genes Dev. 11:3286.[Free Full Text]
  31. Hurlstone, A., H. Clevers. 2002. T-cell factors: turn-ons and turn-offs. EMBO J. 21:2303.[Medline]
  32. Verbeek, S., D. Izon, F. Hofhuis, E. Robanus-Maandag, H. te Riele, M. van de Wetering, M. Oosterwegel, A. Wilson, H. R. MacDonald, H. Clevers. 1995. An HMG-box-containing T-cell factor required for thymocyte differentiation. Nature 374:70.[Medline]
  33. Oosterwegel, M., M. van de Wetering, D. Dooijes, L. Klomp, A. Winoto, K. Georgopoulos, F. Meijlink, H. Clevers. 1991. Cloning of murine TCF-1, a T cell-specific transcription factor interacting with functional motifs in the CD3-{epsilon} and TCR-{alpha} enhancers. J. Exp. Med. 173:1133.[Abstract/Free Full Text]
  34. Pircher, H., T. M. Mak, R. Lang, W. Ballhausen, E. Ruedi, H. Hengartner, R. M. Zinkernagel, K. Burki. 1989. T cell tolerance to Mlsa encoded antigens in T cell receptor V{beta}8.1 transgenic mice. EMBO J. 8:719.[Medline]
  35. Ioannidis, V., F. Beermann, H. Clevers, W. Held. 2001. The {beta}-catenin-TCF-1 pathway ensures CD4+CD8+ thymocyte survival. Nat. Immun. 2:691.[Medline]
  36. Castrop, J., D. van Wichen, M. Koomans-Bitter, M. van de Wetering, R. de Weger, J. von Dongen, H. Clevers. 1995. The human TCF-1 gene encodes a nuclear DNA-binding protein uniquely expressed in normal and neoplastic T-lineage lymphocytes. Blood 8:3050.
  37. Hattori, N., H. Kawamoto, S. Fujimoto, K. Kuno, Y. Katsura. 1996. Involvement of transcription factors TCF-1 and GATA-3 in the initiation of the earliest step of T cell development in the thymus. J. Exp. Med. 184:1137.[Abstract/Free Full Text]
  38. Kubo, S., Y. Itoh, N. Ishikawa, R. Nagasawa, T. Mitarai, N. Maruyama. 1993. The gene encoding mouse lymphocyte antigen Ly-49: structural analysis and the 5'-flanking sequence. Gene 136:329.[Medline]
  39. Korinek, V., N. Barker, P. J. Morin, D. van Wichen, R. de Weger, K. W. Kinzler, B. Vogelstein, H. Clevers. 1997. Constitutive transcriptional activation by a {beta}-catenin-Tcf complex in APC-/- colon carcinoma. Science 275:1784.[Abstract/Free Full Text]
  40. Held, W., D. H. Raulet. 1997. Expression of the Ly49A gene in murine natural killer cell clones is predominantly but not exclusively mono-allelic. Eur. J. Immunol. 27:2876.[Medline]
  41. Vance, R. E., A. M. Jamieson, D. Cado, D. H. Raulet. 2002. Implications of CD94 deficiency and monoallelic NKG2A expression for natural killer cell development and repertoire formation. Proc. Natl. Acad. Sci. USA 99:868.[Abstract/Free Full Text]
  42. Bix, M., R. M. Locksley. 1998. Independent and epigenetic regulation of the interleukin-4 alleles in CD4+ T cells. Science 281:1352.[Abstract/Free Full Text]
  43. Holländer, G. A., S. Zuklys, C. Morel, E. Mizoguchi, K. Mobisson, S. Simpson, C. Terhorst, W. Wishart, D. E. Golan, A. K. Bhan, S. J. Burakoff. 1998. Monoallelic expression of the interleukin-2 locus. Science 279:2118.[Abstract/Free Full Text]
  44. Brantjes, H., J. Roose, M. van de Wetering, H. Clevers. 2001. All Tcf HMG box transcription factors interact with Groucho-related co-repressors. Nucleic Acids Res. 29:1410.[Abstract/Free Full Text]
  45. He, T.-C., A. B. Sparks, C. Rago, H. Hermeking, L. Zawel, L. T. da Costa, P. J. Morin, B. Vogelstein, K. W. Kinzler. 1998. Identification of c-MYC as a target of the APC pathway. Science 281:1509.[Abstract/Free Full Text]
  46. Tetsu, O., F. McCormick. 1999. {beta}-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422.[Medline]
  47. Hecht, A., K. Vleminckx, M. P. Stemmler, F. van Roy, R. Kemler. 2000. The p300/CBP acetyltransferases function as transcriptional coactivators of {beta}-catenin in vertebrates. EMBO J. 19:1839.[Medline]
  48. Brannon, M., M. Gomperts, L. Sumoy, R. T. Moon, D. Kimelman. 1997. A {beta}-catenin/X-Tcf-3 complex binds to the siamois promoter to regulate dorsal axis specification in Xenopus. Genes Dev. 11:2359.[Abstract/Free Full Text]
  49. Rossi, F. M., A. M. Kringstein, A. Spicher, O. M. Guicheret, H. M. Blau. 2000. Transcriptional control: rheostat converted to on/off switch. Mol. Cell 6:723.[Medline]
  50. Biggar, S. R., G. R. Crabtree. 2001. Cell signaling can direct either binary or graded transcriptional responses. EMBO J. 20:3167.[Medline]
  51. Mannervik, M., Y. Nibu, H. Zhang, M. Levine. 1999. Transcriptional coregulators in development. Science 284:606.[Abstract/Free Full Text]
  52. Barker, N., A. Hurlston, H. Muisi, A. Miles, M. Bienz, H. Clevers. 2001. The chromatin remodelling factor Brg-1 interacts with {beta}-catenin to promote target gene activation. EMBO J. 20:4935.[Medline]
  53. Raulet, D. H., W. Held, I. Correa, J. Dorfman, M.-F. Wu, L. Corral. 1997. Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I specific Ly49 receptors. Immunol. Rev. 155:41.[Medline]
  54. Dorfman, J. R., D. H. Raulet. 1996. Major histocompatibility complex genes determine natural killer cell tolerance. Eur. J. Immunol. 26:151.[Medline]
  55. Mehta, I. K., J. Wang, J. Roland, D. H. Margulies, W. M. Yokoyama. 2001. Ly49A allelic variation and MHC class I specificity. Immunogenetics 53:572.[Medline]
  56. Reya, T., M. O’Riordan, R. Okamura, E. Devaney, K. Willert, R. Nusse, R. Grosschedl. 2000. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 13:15.[Medline]



This article has been cited by other articles:


Home page
 BloodHome page
T. Zhang, S. Liu, P. Yang, C. Han, J. Wang, J. Liu, Y. Han, Y. Yu, and X. Cao
Fibronectin maintains survival of mouse natural killer (NK) cells via CD11b/Src/{beta}-catenin pathway
Blood, November 5, 2009; 114(19): 4081 - 4088.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Goux, J. D. Coudert, D. Maurice, L. Scarpellino, G. Jeannet, S. Piccolo, K. Weston, J. Huelsken, and W. Held
Cooperating pre-T-cell receptor and TCF-1-dependent signals ensure thymocyte survival
Blood, September 1, 2005; 106(5): 1726 - 1733.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Stevenaert, K. Van Beneden, V. De Colvenaer, A. S. Franki, V. Debacker, T. Boterberg, D. Deforce, K. Pfeffer, J. Plum, D. Elewaut, et al.
Ly49 and CD94/NKG2 receptor acquisition by NK cells does not require lymphotoxin-{beta} receptor expression
Blood, August 1, 2005; 106(3): 956 - 962.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ioannidis, V.
Right arrow Articles by Held, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ioannidis, V.
Right arrow Articles by Held, W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS